These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1001 related articles for article (PubMed ID: 20692206)

  • 1. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioma-derived mutations in IDH: from mechanism to potential therapy.
    Fu Y; Huang R; Du J; Yang R; An N; Liang A
    Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.
    Weller M; Wick W; von Deimling A
    Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
    Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
    Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.
    Zhu J; Zuo J; Xu Q; Wang X; Wang Z; Zhou D
    Med Hypotheses; 2011 Apr; 76(4):602-3. PubMed ID: 21284999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glioma-derived mutations in isocitrate dehydrogenase 2 beneficial to traditional chemotherapy.
    Fu Y; Huang R; Zheng Y; Zhang Z; Liang A
    Biochem Biophys Res Commun; 2011 Jul; 410(2):218-23. PubMed ID: 21641335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
    Bleeker FE; Lamba S; Leenstra S; Troost D; Hulsebos T; Vandertop WP; Frattini M; Molinari F; Knowles M; Cerrato A; Rodolfo M; Scarpa A; Felicioni L; Buttitta F; Malatesta S; Marchetti A; Bardelli A
    Hum Mutat; 2009 Jan; 30(1):7-11. PubMed ID: 19117336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: possible impact on glioma cell metastasis and chemo-resistance.
    Fu Y; Zheng S; Zheng Y; Huang R; An N; Liang A; Hu C
    Int J Biochem Cell Biol; 2012 May; 44(5):770-5. PubMed ID: 22309944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of isocitrate dehydrogenase in glioma.
    Alexander BM; Mehta MP
    Expert Rev Neurother; 2011 Oct; 11(10):1399-409. PubMed ID: 21955197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndromes and malignant transformation: where the twain shall meet.
    Bhagwat N; Levine RL
    Sci Transl Med; 2010 Oct; 2(54):54ps50. PubMed ID: 20962328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma.
    Agnihotri S; Aldape KD; Zadeh G
    Neurosurg Focus; 2014 Dec; 37(6):E13. PubMed ID: 25434382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis.
    Lin J; Qian J; Yao DM; Li Y; Yang J; Chen Q; Chai HY; Xiao GF; Xu WR
    Clin Biochem; 2011 Jul; 44(10-11):779-83. PubMed ID: 21539821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
    Gross S; Cairns RA; Minden MD; Driggers EM; Bittinger MA; Jang HG; Sasaki M; Jin S; Schenkein DP; Su SM; Dang L; Fantin VR; Mak TW
    J Exp Med; 2010 Feb; 207(2):339-44. PubMed ID: 20142433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isocitrate dehydrogenase mutations in gliomas.
    Waitkus MS; Diplas BH; Yan H
    Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IDH1 mutations in gliomas: when an enzyme loses its grip.
    Frezza C; Tennant DA; Gottlieb E
    Cancer Cell; 2010 Jan; 17(1):7-9. PubMed ID: 20129244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH mutations in acute myeloid leukemia.
    Rakheja D; Konoplev S; Medeiros LJ; Chen W
    Hum Pathol; 2012 Oct; 43(10):1541-51. PubMed ID: 22917530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocitrate dehydrogenase mutations in myeloid malignancies.
    Medeiros BC; Fathi AT; DiNardo CD; Pollyea DA; Chan SM; Swords R
    Leukemia; 2017 Feb; 31(2):272-281. PubMed ID: 27721426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
    Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
    J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 51.